INCY vs MESO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. INCY and MESO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined INCY and MESO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Incyte Corporation is a Wilmington, Delaware based biopharmaceutical company that discovers, develops, and commercializes drugs in oncology, hematology, and dermatology. Its flagship product is Jakafi (ruxolitinib), an oral JAK inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease, which still generates the largest share of company revenue (roughly $758 million in Q1 2026, up about 7%). Beyond Jakafi, Incyte sells the topical cream Opzelura (ruxolitinib) for atopic dermatitis and vitiligo, plus a widening hematology and oncology lineup including Monjuvi/Minjuvi, Niktimvo, and Zynyz, and it funds a broad clinical pipeline of oncology and immunology candidates.

Full INCY guide

Mesoblast Limited is a Melbourne-based biopharmaceutical company founded in 2004 by Dr. Silviu Itescu, who still runs it, and it develops allogeneic (off the shelf) mesenchymal stromal cell medicines for severe inflammatory disease. Its lead product, Ryoncil (remestemcel-L-rknd), was approved by the FDA in December 2024 for steroid-refractory acute graft versus host disease in children two months and older, making it the first FDA-approved mesenchymal stromal cell therapy. The regimen is eight intravenous infusions over four weeks at a list price of about $194,000 per infusion, which puts a full course near $1.55 million before rebates, chargebacks and patient assistance. A commercial team of roughly ten representatives sells into about 45 priority transplant centers that handle around 80 percent of U.S. pediatric transplants, and coverage now reaches more than 250 million insured U.S. lives including fee-for-service Medicaid. Mesoblast also earns royalties on TEMCELL, the same cell technology marketed in Japan by licensee JCR Pharmaceuticals, and holds more than 1,000 granted patents and applications running to at least 2044.

Full MESO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• INCY drivers: Jakafi franchise still growing near-term; Non-Jakafi revenue diversification.
• MESO drivers: Ryoncil's first full year of sales; Label extension into adult graft versus host disease.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is revenue concentration: Jakafi still drives the majority of sales and faces US loss of exclusivity in December 2028, after which generic ruxolitinib is expected to erode the franchise. For MESO, nearly all current revenue comes from a single product in a single small indication, so any manufacturing interruption, reimbursement change or safety signal on Ryoncil would hit the whole business at once.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick INCY if you believe its drivers more; MESO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the INCY and MESO guides.

INCY. Incyte trades at a modest multiple for a profitable biopharma, with a forward P/E around 12x reflecting strong recent earnings growth but investor caution about the 2028 Jakafi cliff. The trailing P/E collapsed from triple digits in early 2025 to the mid-teens through 2026 as earnings normalized. Figures are approximate as of mid-2026 and move with reported results and the share price.

MESO. Mesoblast reports in U.S. dollars under IFRS even though the parent company's functional currency is the Australian dollar, and its fiscal year ends June 30, so figures quoted as fiscal 2026 cover July 2025 through June 2026. Screeners that show a trailing twelve-month revenue near $65 million are running on the period through December 31, 2025 and understate the current run rate, which puts the multiple closer to 17 times sales than 30 times. The audited fiscal 2026 annual report on Form 20-F had not been filed as of mid-August 2026, so the full-year figures above come from the July 2026 quarterly activity statement.

Headline figures (approximate, JULY 2026): INCY shows revenue (ttm) ~$4.8B, q1 2026 revenue ~$1.27B (up ~21% YoY), jakafi q1 2026 net sales ~$758M, cash & marketable securities ~$4.0B; MESO shows market cap ~$2.1B (ADS ~$15.60, ~132M ADS outstanding), ryoncil net revenue (fy2026, year to june 30, 2026) ~$115M, preliminary and unaudited, revenue (h1 fy2026, six months to dec 31, 2025) ~$51.3M, of which ~$48.7M product sales, net loss (h1 fy2026) ~$40.2M.

INCY and MESO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined INCY and MESO exposure against your real portfolio. It is not an investment adviser.